MX2023001570A - Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus. - Google Patents

Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.

Info

Publication number
MX2023001570A
MX2023001570A MX2023001570A MX2023001570A MX2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A
Authority
MX
Mexico
Prior art keywords
compositions
methods
coronavirus infection
treating
beta
Prior art date
Application number
MX2023001570A
Other languages
English (en)
Spanish (es)
Inventor
Jacqueline M Iversen
Thomas A Dahl
Original Assignee
Sen Jam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sen Jam Pharmaceutical Llc filed Critical Sen Jam Pharmaceutical Llc
Publication of MX2023001570A publication Critical patent/MX2023001570A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023001570A 2020-08-06 2021-08-06 Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus. MX2023001570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (1)

Publication Number Publication Date
MX2023001570A true MX2023001570A (es) 2023-05-03

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001570A MX2023001570A (es) 2020-08-06 2021-08-06 Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.

Country Status (10)

Country Link
US (1) US20240033259A1 (https=)
EP (1) EP4192457B1 (https=)
JP (1) JP2023537369A (https=)
KR (1) KR20230048517A (https=)
CN (1) CN116322662A (https=)
AU (1) AU2021321535A1 (https=)
CA (1) CA3188387A1 (https=)
IL (1) IL300406A (https=)
MX (1) MX2023001570A (https=)
WO (1) WO2022032069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION

Also Published As

Publication number Publication date
EP4192457A1 (en) 2023-06-14
AU2021321535A1 (en) 2023-03-23
IL300406A (en) 2023-04-01
EP4192457A4 (en) 2024-09-18
CN116322662A (zh) 2023-06-23
WO2022032069A1 (en) 2022-02-10
CA3188387A1 (en) 2022-02-10
KR20230048517A (ko) 2023-04-11
JP2023537369A (ja) 2023-08-31
EP4192457B1 (en) 2026-03-25
US20240033259A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
RU2015107877A (ru) Способы лечения болезни альцгеймера и фармацевтические композиции
Sanghai et al. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
EA201591610A1 (ru) Ингибиторы кинуренинового пути
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2009008051A (es) Regimen posologico para inhibidores de comt.
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2023001570A (es) Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.
BR112014003981A2 (pt) compostos de pirimido-piridazinona e seu uso
CR20220250A (es) Métodos para el tratamiento de trastornos depresivos
MX2025005357A (es) Inhibidor de parp1 de tipo triciclico fusionado, metodo de preparacion del mismo y uso del mismo
UY39864A (es) Nuevos agentes antivirales derivados de espiropirrolidina
CY1111783T1 (el) Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
BR112023023534A2 (pt) Composição farmacêutica para uso no tratamento de infarto cererbral
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
WO2023166492A3 (en) Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
MX2025010182A (es) Métodos para el tratamiento de las infecciones por gripe